Meeting
2017 ASCO Annual Meeting
A randomized, open-label, multicenter trial of the concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with 5-FU for Chinese squamous esophageal cancer: An interim report from CRTCOESC.
Authors
Ruinuo Jia
Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China
Ruinuo Jia , Tanyou Shan , Fuyou Zhou , Anping Zheng , Lixin Wan , Zhiqiao Xu , Guobao Zheng , Xiaoyong Luo , Yingjuan Zheng , Yanhui Cui , Guifang Zhang , Dan Zhou , Jiachun Sun , Guoqiang Kong , Xiaozhi Yuan , Ruina Yang , Jing Ren , Wei Wang , Xinshuai Wang , Shegan Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02025036
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4063)
DOI
10.1200/JCO.2017.35.15_suppl.4063
Abstract #
4063
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.
First Author: Ruinuo Jia
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
First Author: Yelena Y. Janjigian
Poster
2012 Gastrointestinal Cancers Symposium
Retrospective analysis of neoadjuvant chemoradiotherapy for esophageal cancer: The Knight Cancer Institute experience.
First Author: Faisal A Siddiqui
Poster
2024 ASCO Annual Meeting
Neoadjuvant S-1 plus cisplatin-based chemoradiotherapy compared with surgery alone for locally advanced gastric cancer: Randomized, phase II trial.
First Author: Moonki Hong